The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on existing tariff and trade policies.
All universities are facing uncertainty about federal funding and grants. But because Indiana hasn’t been so dependent on those dollars for building up its life sciences sector, it might be able to forge a new path.
By making the expected blockbuster pill in the U.S., Lilly may be able to avoid the impact of Trump’s sweeping tariffs, including possible levies on pharmaceutical products.
Trial data data showed Lilly’s experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.
Trump’s order contains proposals to further lower the cost of insulin, importing more low-cost drugs and streamlining the federal approval process for some drugs.
It was the second straight sizable increase, suggesting that U.S. drug makers with Irish manufacturing hubs like Indianapolis-based Eli Lilly and Co. could be stockpiling products ahead of any tariffs on the sector.
Pfizer had been hoping the once-daily pill treatment would give it an edge over leading weight-loss treatments like Zepbound from Eli Lilly and Co. and Novo Nordisk’s Wegovy, which are injectable.
The drugmaker accuses Premier Weight Loss of risking patients’ health by selling altered, unsterile versions of its blockbuster drugs Mounjaro and Zepbound.
President Trump’s predecessor, Joe Biden, proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and Wegovy.
Amid uncertainty around federal research funding, universities must explore private support, Purdue University President Mung Chiang told an tech industry group on Tuesday.
The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it.
Indiana Economic Development Corp. spokeswoman Erin Sweitzer said the additional load is what’s needed to build out projects for Eli Lilly and Co. and Meta.
The company said its goal is to reduce wait times for patients seeking access to specialists, creating more opportunities for early diagnosis and intervention.
Critics of the Indiana Economic Development Corp., which receives hundreds of millions in tax dollars each year, have wondered whether the agency has been transparent and fiscally responsible enough.
On March 22, Indianapolis Opera will celebrate its 50th anniversary with a gala at Hilbert Circle Theatre. The event will feature the Indianapolis Symphony Orchestra accompanying a roster of high-profile singers from the opera’s past and present.
“People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of management.”
